AlloVir, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: -
AlloVir Inc is a biopharmaceutical company. The company focuses on developing allogeneic T-cell therapies to combat viral diseases. Their proprietary virus-specific T cell VST therapy platform enables the creation of off-the-shelf VSTs, therapy platform allows AlloVir to generate off-the-shelf VSTs designed to restore immunity in patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. This included: (1) posoleucel (ALVR105), an investigational off-the-shelf multi-virus-specific T cell therapy. (2) ALVR106, an allogeneic, off-the-shelf VST therapy candidate developed to target devastating diseases caused by four respiratory viruses. (3) ALVR107, an allogeneic, off-the-shelf VST therapy candidate designed to target hepatitis B (HBV).
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 456 out of 861
Universe
Global Universe 10890 out of 15176
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the non-India based rated subjects, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
PepGen Inc. |
29.9
Medium
|
393 out of 861 |
AlloVir, Inc. |
31.3
High
|
456 out of 861 |
bluebird bio, Inc. |
34
High
|
580 out of 861 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
AlloVir, Inc.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
AlloVir, Inc.'s Management of ESG Material Risk is Weak